|1.||Montefiori, David C: 42 articles (08/2015 - 03/2002)|
|2.||Mascola, John R: 32 articles (12/2015 - 05/2003)|
|3.||Morris, Lynn: 21 articles (05/2015 - 03/2002)|
|4.||Haynes, Barton F: 20 articles (08/2015 - 06/2006)|
|5.||Seaman, Michael S: 19 articles (11/2015 - 07/2008)|
|6.||Konishi, Eiji: 18 articles (11/2015 - 01/2003)|
|7.||Nabel, Gary J: 17 articles (08/2015 - 11/2004)|
|8.||Stamatatos, Leonidas: 17 articles (06/2015 - 01/2003)|
|9.||Whitehead, Stephen S: 16 articles (12/2015 - 10/2004)|
|10.||Overbaugh, Julie: 16 articles (07/2015 - 01/2006)|
04/05/2011 - "Several studies have emphasized the importance of an early, highly neutralizing antibody response in the clearance of Hepatitis C virus (HCV) infection. "
10/01/2015 - "Neutralizing antibodies have been proven to be highly effective in blocking influenza virus infections. "
01/01/2013 - "The most convincing data suggesting that NAbs might confer protection against HIV-1 infection have been obtained by experiments of passive immunization of newborn macaques with the first generation of human monoclonal broadly neutralizing antibodies (HuMoNAbs). "
07/01/2009 - "However, the efficacy of Ad5 vectors has been limited in humans because exposure to Ad5 infections results in most adults having neutralizing antibodies against Ad5. "
01/01/2009 - "Isolation and chimerization of a highly neutralizing antibody conferring passive protection against lethal Bacillus anthracis infection."
01/01/2015 - "Subcutaneous LLC tumors in mice treated with TGF-β neutralizing antibody exhibited fewer γH2AX foci after irradiation and significantly greater tumor growth delay in combination with fractionated radiation. "
10/01/2011 - "Measles virus (MV) is a promising vector for cancer therapy and multivalent vaccination, but high prevalence of pre-existing neutralizing antibodies may reduce therapeutic efficacy, particularly following systemic administration. "
10/01/2008 - "Moreover, PE-NP-S was shown to be much weaker in inducing vascular leakage syndrome in mice than Mut-I. The LD(50) of PE-NP-S was about 4-fold higher than that of Mut-I. Remarkably, PE-NP-S was of low immunogenicity in development of anti-PE neutralizing antibodies in vivo and was less susceptible to inactivation by anti-PE neutralizing antibodies compared with Mut-I. In conclusion, the resultant PE-NP-S possessed increased cancer therapeutic efficacy and had reduced nonspecific toxicity and immunogenicity, suggesting that it is a potential candidate in cancer therapy."
03/15/2000 - "Although adenoviruses are an attractive vehicle for gene transfer into tissues including various tumors, in vivo adenoviral administration elicits a neutralizing antibody response which eliminates or substantially reduces the efficacy of subsequent treatments. "
11/01/2007 - "Although IFNsalpha have been widely employed for the pharmacological treatment of different types of cancer, the therapeutic efficacy occasionally can be diminished by the appearance of side effects, neutralizing antibodies or tumor resistance. "
11/01/2015 - "Neutralizing antibodies can diminish clinical efficacy of IFN-β in multiple sclerosis patients. "
09/20/2015 - "Although IFNβ therapy has improved treatment options of patients with multiple sclerosis (MS), the long-term efficacy of IFNβs can be compromised due to the development of neutralizing antibodies (NAbs). "
06/08/2004 - "Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis."
02/01/2014 - "Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group."
07/01/2008 - "In this study, we compared four BAB tests, a western blot (WB), a direct binding enzyme-linked immunosorbent assay (ELISA) (dELISA), a capture ELISA (cELISA), and a commercial enzyme immuno-assay (EIA) in 325 multiple sclerosis patients with and without neutralizing antibodies to evaluate the sensitivity and specificity to detect NAB by receiver operating characteristics analysis. "
01/01/1990 - "This recombinant, when administered by either the parenteral or oronasal route, was highly effective in eliciting good levels of rabies-neutralizing antibodies in the sera of dogs and mice. "
07/01/2015 - "Serial rising rabies virus neutralizing antibody titres in serum and cerebrospinal fluid by rapid fluorescent focus inhibition test helped confirm the diagnosis of rabies. "
01/01/2014 - "The rabies virus neutralizing antibody titers was assessed by rapid fluorescent focus inhibition test and all the vaccinees had titers ≥0.5 IU per mL on day 14 which is considered as adequate for protection against rabies. "
06/06/2012 - "Evaluation of an improved rapid neutralizing antibody detection test (RAPINA) for qualitative and semiquantitative detection of rabies neutralizing antibody in humans and dogs."
05/01/2002 - "The determination of the rabies neutralizing antibody (VNA) response after immunization against rabies is an acceptable index of the efficacy of a vaccine and a successful treatment. "
|5.||Human Influenza (Influenza)
07/01/2009 - "The best form of protection against influenza is high-titred virus-neutralizing antibody specific for the challenge strain. "
08/27/2013 - "Protection against influenza is mediated by neutralizing antibodies, and their induction at high and sustained titers is key for successful vaccination. "
05/01/2011 - "Neutralizing antibody may be a better correlate of human protection against pathogenic influenza strains and should be considered for vaccine efficacy."
07/01/2013 - "Here we demonstrate that adeno-associated viruses (AAV) encoding two such broadly neutralizing antibodies are protective against diverse influenza strains. "
01/01/2012 - "Here, we used this new format to measure the cytopathic effect (CPE) of the 2009 influenza A (H1N1) virus and the efficacy of neutralizing antibodies in human sera to this virus. "
|5.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|6.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|10.||Complement System Proteins (Complement)
|3.||Heterologous Transplantation (Xenotransplantation)